Swiss Authorized Representative (CH-REP) Provider Directory
This directory helps non-Swiss medical device and IVD manufacturers evaluate CH-REP providers with clear operating criteria: mandate scope quality, speed to compliant onboarding, vigilance support readiness, and annual total-cost predictability.
Keyword intent captured on April 9, 2026 from live search checks: "swiss authorized representative medical device", "ch-rep requirements switzerland", "ch rep cost", "ch rep timeline", and "swissmedic authorized representative".
Compare +50 Swiss Authorized Representative providers Do I Need a CH-REP?Why this directory focuses on operations, not marketing claims
Most CH-REP buying mistakes happen before contract signature. Teams compare headline fees and response-time promises, but they do not test execution detail. During onboarding, this creates avoidable delays: unclear mandate boundaries, inconsistent technical-document access rules, and confusion about who owns Swissmedic-facing communication during urgent events. A stronger provider selection process asks for operating evidence first and commercial terms second.
In practice, your CH-REP provider should be treated as a regulated operating partner, not a mailbox service. The provider must fit your portfolio risk profile, documentation maturity, and post-market signal volume. If your internal QMS is highly mature, you may need light-touch representation with strict role boundaries. If your internal controls are still scaling, you may need deeper governance support and faster escalation pathways. This is why Cruxi positions provider comparison around practical planning tools that expose scope, timeline, and budget assumptions before interviews.
A second reason to use this framework is governance quality under pressure. Teams often evaluate providers during expansion or remediation periods when time is constrained. Under pressure, broad claims sound convincing. Structured pre-work reduces that risk. If you arrive with a scope-gap score, a transition timeline model, and a multi-scenario annual budget, provider conversations become specific and comparable. You can challenge assumptions, identify hidden dependencies, and reduce the chance of signing a contract that under-scopes high-risk obligations.
Use these 3 utility calculators before provider interviews
Score mandate and governance gaps across labeling, technical-file access, escalation ownership, and evidence traceability.
Estimate realistic onboarding windows by portfolio complexity, class mix, translation load, and supplier dependencies.
Model base, vigilance, and change-management cost exposure with conservative, expected, and high-activity scenarios.
Running these tools first helps you compare providers on method quality, not only brochure language.
Provider evaluation rubric for CH-REP engagements
1) Mandate architecture clarity
Ask how the provider structures the written mandate for MedDO/IvDO obligations, technical-document access mechanics, and communication responsibilities. Strong providers explain what they do, what they do not do, and where your team retains explicit accountability.
2) Transition controls and critical path management
Ask for a transition plan that identifies critical-path dependencies: artwork updates, technical-document completeness checks, supplier data handoffs, and authority-facing contact workflows. Vague timeline estimates are a leading indicator of downstream delay risk.
3) Vigilance and escalation readiness
Ask for concrete escalation mechanics: who responds first, where decisions are logged, and how response SLAs are measured. In high-signal periods, escalation quality determines whether events stay controlled.
4) Evidence discipline
Provider quality shows in retrieval speed and evidence consistency. Request examples of artifact indexing practices, version control expectations, and change-log standards for onboarding and ongoing maintenance.
5) Cost transparency and change-order triggers
Ask which events trigger additional fees and how those events are defined. Hidden cost exposure usually appears in change events, not the base retainer.
Cross-links for related workflows
Sources and citations
- Swissmedic: Swiss authorised representative (CH-REP) - https://www.swissmedic.ch/swissmedic/en/home/medical-devices/market-access/ch-rep.html
- Swissmedic FAQ (MedDO / IvDO) - https://www.swissmedic.ch/swissmedic/en/home/medical-devices/regulation-of-medical-devices/faq.html
- Fedlex: Medical Devices Ordinance (MedDO) - https://www.fedlex.admin.ch/eli/cc/2020/552/en
- Fedlex: Ordinance on In Vitro Diagnostic Medical Devices (IvDO) - https://www.fedlex.admin.ch/eli/cc/2022/291/en
Disclaimer: Educational planning content only. This page does not provide legal advice.